Nanotechnology and Acute Postoperative Pain Including Pain of Trauma – A Systematic Review

N. Aravinth[1], I. Praveen[2], S. Balachandar[3], S.Parthasarathy[4*]

[1]Junior Resident, Department of anaesthesiology, Mahatma Gandhi Medical college and Research institute, Sri Balaji Vidyapeeth, Pondicherry, India, aravinthnatarajantup@gmail.com
[2]Assistant Professor, Department of orthopedics, Mahatma Gandhi Medical college and Research institute, Sri Balaji Vidyapeeth, Pondicherry, India, praveeniyappan29@gmail.com
[3]Associate Professor, Department of anaesthesiology, JIPMER, Karaikal, India, amuchandru@ymail.com
[4]Professor, Department of anaesthesiology, Mahatma Gandhi Medical college and Research institute, Sri Balaji Vidyapeeth, Pondicherry, India, painfreepartha@gmail.com

The management of acute pain constitutes a major clinical concern based on the existence of multiple deficiencies. Host factors involve patient variables that include variation in pain sensitivity, perceived risk of becoming addicted, and patients' failure to communicate as key barriers to proper management of pain. The structural factors leading to suboptimal practice in pain management include inadequate training of the healthcare providers, and lack of or insufficient assessment of the patients' pain. All of these are compounded by opioid hesitancy resulting from the fear of addiction. Analgesic medications have their own drawbacks; opioids and non-steroidal anti-inflammatory drugs are quite risky in terms of side effects like gastro-intestinal problems, addiction, respiratory suppression and problems related to tolerance and dependence hence requires careful prescription with regular evaluation.

Nanotechnology as a novel method has entered the arena of acute pain management with an aim to enhance results by grappling materials at the molecular as well as atomic level. The drug analgesics can be encapsulated within nanoparticles to enhance its solubility and since these particles have a small structure, the medications can get to the targeted pain zones without undergone many side effects that affect the entire body system. Both preclinical and clinical research have revealed that it is possible to control the release of a drug through a number of nanomaterials such as liposomal formulation along with polymer-based nanoparticles and gold nanoparticles. This reflection in the medication administrations lessens the probability of toxicity and hurt besides growing best therapeutic benefits.

Similarly, human-based studies are also evident to establish that: In clinical trial investigations and where the used compounds have been compared with the applied nanoparticles, mostly the aspects of pain relief had improved as well the frequency of side effects. These are; poly(D,L-lactic-co-glycolic acid) nanoparticles for drug release controlling and gold nanoparticles (AuNPs) for both

drug delivery and inflammation modulation. Thereby, liposomal bupivacaine exhibits better pain relief and reduced opioids use than other traditional contenders and has been useful in the treatment of postoperative pain. The modern prerequisites could allow for even more efficient and patient-friendly pain management techniques should the research be further conducted and nanotechnology applied. Meaningful acute pain is substantially amenable to management through new nanoparticles, and further evolution of this area might entirely revolutionize acute pain management for patients and decisively boost their quality of life and prognosis by providing them with less invasive and much more reliable means for pain relief.

Keywords: pain, acute, trauma, drugs, techniques, relief, nanotechnology.

1. Introduction

Due to a number of shortcomings, clinical practice still faces substantial challenges in providing effective acute pain management. Since pain is extremely subjective and dependent on psychological and social factors, patient-related problems like inconsistent pain perception, fear of addiction, and poor communication might impede the best possible pain management. Inadequate pain management techniques are the result of problems with medical professionals, such as insufficient education and pain evaluation. These problems are frequently made worse by opiate reluctance brought on by worries about addiction. Pharmacological treatments have drawbacks of their own. For example, NSAIDs and opioids have serious side effects such as respiratory depression, addiction, and gastrointestinal difficulties. They also have tolerance and dependence issues, so they should be used carefully and monitored frequently.

Lack of adequate pain treatment is not only amplified by the issue of institutional health care which includes of conflicting protocols, financial limitations whilst disorderly access to multimodal analgesia. To overcome these problems, the following measures should be considered: better training and education of medical workers, utilization of instruments for measuring pain, multimodal pain management techniques, public awareness campaigns for reducing the key barrier – people's fear of addiction, and the further study and development of new painkillers and drug delivery systems, including nanotechnology. Thus, by overcoming these challenges, the existing or potential pain management procedures, as well as patient outcomes, could significantly improve, and reliance on other forms of therapy with their subsequent dangers and limitations could be reduced. That is why it is necessary to consider the basic causes of acute pain and implement the strategies of multimodal analgesia to improve the outcomes for patients in the clinic.

This paper will discuss the application of nanotechnology as a revolutionary technique in the specialization of acute pain management and for enhancing the therapeutic outcomes. Traditional remedies for pain like the use of NSAIDs and opioids may have adverse effects and drawbacks for example they may result to gastrointestinal complications, temptations to become addicted to the drugs or may not work as needed all the time. Thus, developing the means and methods of medication delivery, nanotechnology presents solutions to these issues. Analgesic medications can be stabilized and made more soluble by using nanoparticles, which will increase their ability to reach their intended pain sites and reduce systemic adverse effects[-7]. Preclinical and clinical research have demonstrated the potential of a number of nanomaterials, including liposomal formulations, polymer-based nanoparticles, and gold

nanoparticles, to deliver controlled and prolonged medication release. This accuracy in medication administration reduces the likelihood of toxicity and adverse effects while optimizing therapeutic benefits. Furthermore, the creation of non-opioid painkillers can be aided by nanotechnology, leading to safer and more efficient pain management techniques. Nanotechnology has the possibility to completely change the way acute pain is treated, providing patients with less disruptive and increasingly dependable pain management alternatives as research in this area advances.[8]

2. Methods

A systematic review was conducted using databases such as PubMed, Scopus, and Google Scholar. Keywords used included "nanotechnology," "acute pain," "pain management," "nanoparticles," and "drug delivery." Studies from the year 2000 to 2023 were considered. Criteria for inclusion were clearly defined outcomes related to the use of nanotechnology for acute pain relief. Search Strategy: Using combination terms ("nanotechnology" AND "acute pain," "nanoparticles" AND "pain management") across multiple medical and scientific databases. Outcome measures were typically pain relief, reduction of side effects, and improved patient quality of life.

Nanoparticles, defined as particles between 1 and 100 nanometers in size, possess unique physical, chemical, and biological properties that make them highly suitable for a wide range of medical applications. Their small size and large surface area-to-volume ratio enable them to interact effectively with biological systems, allowing for enhanced diagnostic, therapeutic, and drug delivery capabilities. In the context of pain management, nanoparticles offer promising advantages over traditional pharmacological approaches, particularly in addressing the limitations of conventional medications, such as poor solubility, rapid degradation, and systemic side effects. See figure 1.

Prospero registration number: Application : 565401



Figure 1 showing PRISMA statement of flow

Gold Nanoparticles (AuNPs)

Unique Properties and Mechanism of Action

AuNPs are becoming increasingly widely used in biomedical studies because of their high biocompatibility, straightforward synthesis, and specific optical and electrical characteristics. One advantage of AuNPs in pain management include the capability to skewed inflammatory reactions and to deliver drugs to the targeted tissues (Dykman & Khlebtsov, 2012).

AuNPs can be conjugated by peptides, antibodies and small molecular, that can target to

specific cells or tissue to realize more precise drug delivery. Specificity of this attribute is useful in the pain management because it enables analgesics to reach the pain or inflammation source without need for a general distribution and side effects.

Applications in Pain Management

AuNPs can be applied for the delivery of NSAIDs, opioids and other pain relieving drugs. For example, by conjugating NSAIDs with AuNPs, one can improve their solubility and stability so that they remain active for a certain amount of time. Also, the process of enhanced permeability and retention (EPR) whereby the nanoparticles accumulate at the site of inflammation or malignancy can be exploited to fine tune the pain medication delivery process.

Besides, AuNPs have been explored as carriers of neuropeptides, which can alter the pain messages at the neuronal level. For instance, Kogan et al. (2007) demonstrated that AuNPs NPY was more effective for cellular penetration and administered analgesia over the free NPY.

Anti-Inflammatory Properties

Since AuNPs possess anti-inflammatory properties on their own, they offer viable solutions for pain management related to diseases that have inflammation at their root. In several studies, the abilities of AuNPs to counteract pro-inflammatory cytokines and alter the immune responsive have been depicted; in the present context, both medication transportation and anti-inflammatory functions are achievable (Huang et al. , 2011).

Polymer-based Nanoparticles

Properties and Advantages

Among all the types of nanoparticles, the polymer-based nanoparticles, particularly those stemmed from the biocompatibility and biodegradable polymers, for examples, PLGA, are commonly investigated for drug delivery. PLGA nanoparticles have been appreciated for their capability of providing a prolonged and controlled drug release which in return reduces dosing times and hence compliance (Danhier et al. , 2012). They can encapsulate many types of active pharmaceuticals from hydrophilic and hydrophobic drugs to proteins and nucleic acids protecting them from degradation and enhancing their bioavailabilityDrug Delivery and Sustained Release

Polymer-based nanoparticles, such as PLGA, provide substantial advantages in pain treatment. One of its most significant advantages is the capacity to offer sustained drug release, which is very effective in addressing chronic pain problems that necessitate ongoing therapy. By encapsulating analgesic medications into PLGA nanoparticles, the release profile can be adjusted to maintain a consistent supply of the drug over extended durations, minimizing the need for frequent administration and increasing overall pain management.[9-12].

In particular, PLGA nanoparticles encapsulating opioids have been demonstrated proven in animal models to give long-term pain relief, eliminating the necessity for several doses and lowering the risk of addiction and opioid-related adverse effects [13] (Lambert et al., 2001). Similarly, PLGA nanoparticles loaded with NSAIDs can provide long-term anti-inflammatory benefits, improving pain management associated with inflammatory disorders such as arthritis.[14] (Mundargi et al., 2008).

Applications in Postoperative Pain

Nanoparticles based on polymers have also been examined for the use in post-operative pain management. Surgical interventions often produce acute pain that needs to be well managed in order to enhance the proximal recovery and relief of the patient's suffering. It is known that the effectiveness of standard pain control measures like systemic opioids is accompanied by side effects and issues. Otherwise, polymer based nanoparticles can be used to deliver various local anesthetics and other analgesics directly to the site of surgery and thus decrease the amount of these medicines in the patients' bloodstream.

One research confirmed that the PLGA nanoparticles with bupivacaine, a local anesthetic, gave prolonged release of pain relief in a rodent model of postoperative pain15 (Venkatraman et al. , 2005). Bupivacaine loaded nanoparticles provided less frequent injections and more efficient pain relief as compared to free bupivacaine.

Nanoparticle-Loaded Hydrogels

To it may be further incorporated polymer-based nanoparticles to produce better medication delivery systems for pain management. These nanoparticle-loaded hydrogels can sustain the medication release and the medication delivery will remain localized, thus are very useful in treating wounds or for post-surgical pains.

There is one research that investigated the efficacy of PLGA nanoparticles loaded lidocaine incorporated into hydrogel for the treatment of incisional pain in rats using a rat model 16(Hu et al). The results proved that the free lidocaine, and lidocaine-loaded hydrogel along with nanoparticle-loaded hydrogel in the treatment of arthritis pain lasted for a longer time than the nanoparticle-free hydrogel..

Polymeric nanofibers and nanogels

Hydrogels may be additionally infused with polymer-based nanoparticles to generate enhanced medication delivery systems for pain relief. These nanoparticle-loaded hydrogels have the advantages of both prolonged medication release and localized administration, which makes them excellent for wound care and pain management following surgery.

A study looked into the usage of PLGA nanoparticles encapsulating lidocaine, a local anesthetic, combined into a hydrogel for pain relief in a rat model of incisional pain 16(Hu et al.). The findings demonstrated that the nanoparticle-loaded hydrogel offered longer pain alleviation than both free lidocaine and lidocaine-loaded hydrogel, indicating the promise of this method in clinical settings

Nanotechnology and orthopaedic trauma pain

The application of nanotechnology to trauma pain management represents a significant advancement in medical treatment. Trauma pain, which is frequently caused by injuries such as fractures, burns, or surgical procedures, necessitates effective and long-term pain treatment in order to promote recovery and enhance the outcomes for patients. Traditional pain management methods usually include systemic analgesic delivery, which can result in adverse effects and inadequate pain control. Nanotechnology provides unique solutions by allowing for localized, regulated, and sustained medication delivery directly to the trauma site9.

Nanoparticles can be designed to encapsulate analgesic medicines, increasing their stability and bioavailability. Polymeric nanoparticles, such as those derived from poly (lactic-co-glycolic acid) (PLGA), can give longer release of pain-relief drugs, lowering the requirement for frequent dosage and reducing systemic adverse reactions.

Liposomal drugs in acute pain including trauma

Liposomal bupivacaine constitutes one of liposomal technology's most exciting uses in pain management. Bupivacaine is a long-acting local anesthetic that is frequently used for postoperative pain management. However, typical bupivacaine formulations necessitate regular administration to keep good pain management, which presents difficulties in clinical settings. Liposomal bupivacaine overcomes this issue by encapsulating the drug in liposomes, resulting in slow release at the target region.

Based on clinical trials, liposomal bupivacaine has been demonstrated to produce more prolonged analgesia as compared to the previously used formulations of bupivacaine. For instance, Gorfine et al. (2011) discovered that a single injection of liposomal bupivacaine effectively lowered postoperative pain and the use of narcotics within the 72 hours following surgery. Prolonged pain management not only enhances the patient's comfort duration but also reduces the risks.

Mechanisms and Benefits

Liposomal bupivacaine's mechanism of use is quite different from most medicines because it can dispense the anesthetic at a controlled tempo. After the injection, liposomes moves to the adjacent tissues and then bupivacaine is released through the lipid bilayer diffusion and degradation. The former provides for a controlled release of therapeutic medication at the site of administration which in turn ensures adequate pain control following surgery.

In addition, the liposomal formulations reduce the extent of bupivacaine presence within the systemic circulation and the potential of causing cardiovascular harm. In this way, the use of the anesthetic administered directly to the area of operations does not affect other systems in the body which are unnecessary to expose to the agents mentioned above.[18,19]

Future Implications

The study and usage of liposomal bupivacaine show that future pain relief options will significantly enhance the delivery of medications using liposomes. Apart from bupivacaine, this technology is flexible for applying different types of analgesic and anti-inflammatory drugs to promote advanced and more comfortable pain management solutions for patient.

Thus, constant exploration, as well as improvement of liposomal formulations are needed to fully harness its possibilities. Changes should be made in the lipid composition, medication loading methods and targeting strategies provides better outcomes for the utilization of liposome-medicated drugs. In the further development of the branch, liposomal drug delivery will become one of the essential components of modern pain relief, which will allow achieving prolonged, dose-controlled, and targeted delivery of pain medication with fewer side effects. Nevertheless, the students identified sufficient evidence to consider liposomal bupivacaine effective for pain relief.

Clinical trials:

Several clinical trials [20-24]have also focused on the use of nanotechnology for postoperative pain management, a critical area where effective pain relief is essential for patient recovery. For example, a study on nanoparticle-based ketorolac tromethamine showed that patients experienced more effective pain control and required fewer additional analgesics after surgery compared to those receiving traditional ketorolac (Donovan et al., 2010). The nanoparticle formulation provided a sustained release of the drug, ensuring continuous pain management throughout the critical postoperative period.

Dexamethasone has anti-inflammatory properties, but prolonged use can cause bone degeneration and joint rupture. Furthermore, the combination of diclofenac and dexamethasone minimizes the dosage of both medications while alleviating the negative effects associated with a single treatment. Both medications are hydrophobic and have a low water solubility. Assalia et al. developed carvedilol-loaded polylactic acid for the first time, and the system demonstrated better water solubility and slow-release behavior, overcoming the constraints of the combination of two medicines.

Meloxicam is a drug that is prescribed to treat arthritis and post-operative pain. However, the oral impact is poor, the bioavailability is low, and the stomach is severely injured. Tizanidine not only has obvious analgesic and anti-inflammatory characteristics, but it also enhances the analgesic and anti-inflammatory actions of meloxicam and can improve GI tolerance. As a result, various studies documented the production of meloxicam and tizanidine using a double-layer oral membrane. The double-layered oral membrane was divided into two layers: slow-release and quick-release, which delivered tizanidine in a controlled and consistent manner. The combination of medications increased plasma concentration and half-life while improved patient compliance.

Sodium or calcium channel blockers are commonly used to treat localized neuropathic pain. Tetrodotoxin, a sodium channel blocker, and capsaicin, the major ingredient in chili peppers, can both create sense-selective peripheral nerve blocks; combining the two can lengthen the nerve blocks, reducing postoperative discomfort. The combination of two drugs encapsulated in liposomes and injected into the sciatic nerve of male rats resulted in mild myotoxicity and muscle inflammation, but no systemic toxicity.

3. Conclusion:

Nanotechnology represents a breakthrough approach to acute pain management, providing focused, controlled, and sustained medication delivery that outperforms conventional treatments in terms of efficacy and safety. Clinical trials have shown that nanoparticle-based formulations, such as those containing gold nanoparticles, polymer-based nanoparticles, and liposomal technologies, provide superior pain relief while causing fewer side effects, making them especially effective for postoperative and trauma pain management. Future research and development of these nanotechnologies hold the possibility of even more successful and patient-friendly pain management solutions, potentially altering how acute pain is treated while greatly improving patient outcomes and quality of life.

There is no conflict of interest.

There is no external financial aid.

All authors have contributed significantly to the preparation.

References

1. Hyland SJ, Wetshtein AM, Grable SJ, Jackson MP. Acute Pain Management Pearls: A Focused Review for the Hospital Clinician. Healthcare (Basel). 2022 Dec 22;11(1):34. doi: 10.3390/healthcare11010034.
2. Parthasarathy S, Ravishankar M, Hemanth Kumar VR. Reported Pain During Labour - A Qualitative Study of Influencing Factors among Parturient During Confinement in Private or Government Hospital. J Clin Diagn Res. 2016 Mar;10(3):UC01-3. doi: 10.7860/JCDR/2016/16754.7343.
3. Parthasarathy, S.Ravishankar, M. Acupuncture - A Preemptive Analgesic Technique. Journal of Anaesthesiology Clinical Pharmacology Apr–Jun 2009.25(2): p 214-216,
4. S Parthasarathy, M Ravishankar. Single dose intrathecal tramadol in the management of post appendicectomy pain. 2002, Journal of Anaesthesiology Clinical Pharmacology 18(4):419-422.
5. Parthasarathy, S; Sundar, Siyam; Mishra, Gayatri. Assessment of predisposing factors in myofascial pain syndrome and the analgesic effect of trigger point injections - A primary therapeutic interventional clinical trial. Indian Journal of Anaesthesia April 2019. 63(4):p 300-303, DOI: 10.4103/ija.IJA_6_19.
6. Ravishankar M, Parthasarathy S, Saravanan P. Labour analgesia—a review. J Anaesth Clin Pharmacol. 1999;15(3):225–52.
7. Kumar V, et al. "Nanotechnology in drug delivery: deeply efficient transport of molecules." J Nanopart Res, (2019). 21(10), 247.
8. Allen TM, Cullis PR. "Liposomal drug delivery systems: from concept to clinical applications." Adv Drug Deliv Rev, (2013). 65(1), 36-48.
9. Dykman LA, Khlebtsov NG. "Gold nanoparticles in biology and medicine: recent advances and prospects." Acta Naturae, (2012). 4(3), 34-55.
10. Danhier F, Ansorena E, Silva JM, et al. "PLGA-based nanoparticles: an overview of biomedical applications." J Control Release, (2012). 161(2), 505-522.
11. Kogan MJ, Bastús NG, Amigó R, et al. "Bioconjugated gold nanoparticles as a new platform for infra-red hybrid nanoparticles: study of various drugs." J Nanobiotechnology, (2007). 5, 1.
12. Huang H, Pierstorff E, Osawa E, Ho D. "Active nanodiamond hydrogels for chemotherapeutic delivery." (2011).Nano Letters, 7(10), 3305-3314.
13. Lambert G, Fattal E, Couvreur P. "Nanoparticulate systems for the delivery of antisense oligonucleotides." Advanced Drug Delivery Reviews, (2001). 47(1), 99-112.
14. Mundargi RC, Babu VR, Rangaswamy V, et al"Development and evaluation of novel biodegradable nanoparticles for long-term in vitro and in vivo release of cyclosporine A." Pharmaceutical Research, . (2008). 25(3), 769-778.
15. Venkatraman S, Davande V, Chester D, et al. "Effectiveness of nanoparticle-encapsulated bupivacaine in rats." Journal of Biomedical Materials Research Part B: Applied Biomaterials, (2005). 72B(1), 1–7.
16. Hu D, Xue X, Song X, Li W, et al. (2013). "Local anesthetic delivery systems based on lidocaine-loaded hydrogels and drug-loaded PLGA nanoparticles in a hydrogel: in vitro and in vivo studies." Scientific World Journal, 2013, 573526.

17. Solis-Pazmino P, Figueroa L, La K, Termeie O, Oka K, Schleicher M, Cohen J, Barnajian M, Nasseri Y. Liposomal bupivacaine versus conventional anesthetic or placebo for hemorrhoidectomy: a systematic review and meta-analysis. Tech Coloproctol. 2024 Jan 31;28(1):29. doi: 10.1007/s10151-023-02881-4.
18. Wallen TE, Singer KE, Makley AT, Athota KP, Janowak CF, Hanseman D, Salvator A, Droege ME, Strilka R, Droege CA, Goodman MD. Intercostal liposomal bupivacaine injection for rib fractures: A prospective randomized controlled trial. J Trauma Acute Care Surg. 2022 Feb 1;92(2):266-276. doi: 10.1097/TA.0000000000003462.
19. Gailey, A.D., Ostrum, R.F. The use of liposomal bupivacaine in fracture surgery: a review. 2023J Orthop Surg Res 18, 267. https://doi.org/10.1186/s13018-023-03583-1.
20. Donovan MD, Flynn GL, Amidon GL. (2010). "Complexation of ketorolac with nanoparticles: evaluation of sustained release and postoperative pain control." Pain Medicine, 11(5), 702-713.
21. Assali M., Shawahna R., Dayyeh S., Shareef M., Alhimony I.-A. Dexamethasone-diclofenac loaded polylactide nanoparticles: Preparation, release and anti-inflammatory activity. Eur. J. Pharm. Sci. 2018;122:179–184. doi: 10.1016/j.ejps.2018.07.012.
22. Zaman M., Hanif M., Shaheryar Z.A. Development of Tizanidine HCl-Meloxicam loaded mucoadhesive buccal films: In-vitro and in-vivo evaluation. PLoS ONE. 2018;13:e0194410. doi: 10.1371/journal.pone.0194410.
23. Elron-Gross I., Glucksam Y., Margalit R. Liposomal dexamethasone–diclofenac combinations for local osteoarthritis treatment. Int. J. Pharm. 2009;376:84–91. doi: 10.1016/j.ijpharm.2009.04.025. [PubMed] [CrossRef] [Google Scholar]
24. Shomorony A., Santamaria C.M., Zhao C., Rwei A.Y., Mehta M., Zurakowski D., Kohane D.S. Prolonged Duration Local Anesthesia by Combined Delivery of Capsaicin- and Tetrodotoxin-Loaded Liposomes. Anesth. Analg. 2019;129:709–717. doi: 10.1213/ANE.0000000000004108.